AU2017289315B2 - Heteroaromatic derivatives as NIK inhibitors - Google Patents

Heteroaromatic derivatives as NIK inhibitors Download PDF

Info

Publication number
AU2017289315B2
AU2017289315B2 AU2017289315A AU2017289315A AU2017289315B2 AU 2017289315 B2 AU2017289315 B2 AU 2017289315B2 AU 2017289315 A AU2017289315 A AU 2017289315A AU 2017289315 A AU2017289315 A AU 2017289315A AU 2017289315 B2 AU2017289315 B2 AU 2017289315B2
Authority
AU
Australia
Prior art keywords
substituted
4alkyl
optionally
atoms
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017289315A
Other languages
English (en)
Other versions
AU2017289315A1 (en
Inventor
Simon Richard Green
Gerhard Max GROSS
George Hynd
Edgar Jacoby
Janusz Jozef Kulagowski
Yannick Aimé Eddy Ligny
Calum Macleod
Samuel Edward MANN
Lieven Meerpoel
Olivier Alexis Georges Querolle
Ian Stansfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2017289315A1 publication Critical patent/AU2017289315A1/en
Application granted granted Critical
Publication of AU2017289315B2 publication Critical patent/AU2017289315B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017289315A 2016-06-30 2017-06-29 Heteroaromatic derivatives as NIK inhibitors Ceased AU2017289315B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16177104 2016-06-30
EP16177104.3 2016-06-30
PCT/EP2017/066120 WO2018002217A1 (en) 2016-06-30 2017-06-29 Heteroaromatic derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
AU2017289315A1 AU2017289315A1 (en) 2019-01-24
AU2017289315B2 true AU2017289315B2 (en) 2021-04-01

Family

ID=56296645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017289315A Ceased AU2017289315B2 (en) 2016-06-30 2017-06-29 Heteroaromatic derivatives as NIK inhibitors

Country Status (9)

Country Link
US (1) US11136311B2 (https=)
EP (1) EP3478675B1 (https=)
JP (1) JP6936815B2 (https=)
KR (1) KR102517352B1 (https=)
CN (1) CN109641882B (https=)
AU (1) AU2017289315B2 (https=)
CA (1) CA3027416A1 (https=)
ES (1) ES2805976T3 (https=)
WO (1) WO2018002217A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな置換されたシアノインドリン誘導体
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
UA130430C2 (uk) 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
JP7499284B2 (ja) 2019-06-25 2024-06-13 インベンティスバイオ カンパニー リミテッド 複素環化合物、その製造方法及びその使用方法
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
MX2013011908A (es) 2011-04-12 2014-03-27 Alzheimer S Inst Of America Inc Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
CA2946164A1 (en) 2014-05-22 2015-11-26 The University Of Sydney Omega-3 analogues
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
NZ729618A (en) * 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな置換されたシアノインドリン誘導体
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
CA3027416A1 (en) 2018-01-04
JP2019521097A (ja) 2019-07-25
EP3478675B1 (en) 2020-04-22
US20190359598A1 (en) 2019-11-28
CN109641882A (zh) 2019-04-16
ES2805976T3 (es) 2021-02-16
KR20190025644A (ko) 2019-03-11
WO2018002217A1 (en) 2018-01-04
JP6936815B2 (ja) 2021-09-22
CN109641882B (zh) 2022-10-28
US11136311B2 (en) 2021-10-05
AU2017289315A1 (en) 2019-01-24
EP3478675A1 (en) 2019-05-08
KR102517352B1 (ko) 2023-03-31

Similar Documents

Publication Publication Date Title
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
AU2017286380B2 (en) Azabenzimidazole derivatives as PI3K beta inhibitors
AU2017209935B2 (en) New substituted cyanoindoline derivatives as NIK inhibitors
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AU2017208555B2 (en) New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
AU2017289317B2 (en) Cyanoindoline derivatives as NIK inhibitors
CN104520290A (zh) 酰氨基螺环酰胺和磺酰胺衍生物
AU2014259477A1 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
AU2018297592B2 (en) New substituted azaindoline derivatives as NIK inhibitors
RU2780577C2 (ru) Новые замещенные производные азаиндолина в качестве ингибиторов nik
HK40097413A (en) Heterocyclic compounds as immunomodulators
HK40097413B (en) Heterocyclic compounds as immunomodulators
HK1261385A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1261385B (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1216316B (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired